| LIQUIDIA CORP. DL-,001 |
| USA |
| Gesundheit |
| US53635D2027 / A2JRNS |
| LT4 (Frankfurt) / LQDA (NASDAQ) |
| FRA:LT4, ETR:LT4, LT4:GR, NASDAQ:LQDA |
| - |
| https://liquidia.com/ |
|
Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and..
>Volltext.. |
| 5814.97 Mio. EUR |
| 5726.06 Mio. EUR |
| 397.63 Mio. EUR |
| 150.15 Mio. EUR |
| 122.23 Mio. EUR |
| 1.38 EUR |
| 161.29 Mio. EUR |
| 250.6 Mio. EUR |
| 147.89 Mio. EUR |
| 1.5 |
| 2307.06% |
| - |
| - |
| - |
| - |
| 2 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 1.056.557 Euro. |
| LIQUIDIA |
| 30.09.26 |
|